Experimental studies of the use of DTPA and other agents to limit the systemic burden of plutonium after wound contamination.
D000614:Aminocaproates / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D001822:Body Burden; D002019:Bufexamac / Q000008:administration & dosage / Q000627:therapeutic use; D006224:Cricetinae; D004347:Drug Interactions; D005260:Female; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D004369:Pentetic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D011005:Plutonium / Q000008:administration & dosage / Q000378:metabolism; D051381:Rats; D013997:Time Factors; D014018:Tissue Distribution; D014947:Wounds and Injuries / Q000378:metabolism
D000614:Aminocaproates; D006877:Hydroxamic Acids; D009539:Nicotinic Acids; D002019:Bufexamac; D011005:Plutonium; D004369:Pentetic Acid